When you buy through links on our site , we may realize an affiliate committal . Here ’s how it work .
Pfizer and BioNTech have officially submitted a request to the U.S. Food and Drug Administration ( FDA ) to authorize their COVID-19 vaccine for baby age 5 to 11 .
" With new cases in kid in the U.S. carry on to be at a high spirit level , this submission is an important step in our ongoing movement against # COVID19 , " Pfizertweetedon Thursday ( Oct. 7 ) . " We ’re committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat . "
Last calendar month , the companies announced that their COVID-19 vaccine was good and efficacious for children between the age of 5 and 11 , base on data from their latest clinical trial . The young participants were given a lower dose of the vaccine than the Cupid’s disease given to old children and adults , Live Science antecedently reported .
Related : Coronavirus variants : Here ’s how the SARS - CoV-2 mutants stack up
The young children arise an antibody reaction comparable to that of people 16 to 25 year of eld . They also allow the vaccine well , and the side effect were similar to those seen in older age group , the society said .
presently , the FDA has approved the Pfizer - BioNTech vaccinum for those 16 years of age and old and has given an emergency approving for children eld 12 to 15 . It ’s the only vaccine in the U.S. authorized to be given to children untested than 18 years of age .
— 11 ( sometimes ) venomous disease that hop across metal money
— 14 coronavirus myths bust by scientific discipline
— The deadliest viruses in history
The FDA has tentatively scheduled a encounter of its Vaccines and Related Biological Products Advisory Committee to discuss and review the data on Oct. 26 .
" We know from our vast experience with other pediatric vaccinum that children are not small adults , and we will conduct a comprehensive rating of clinical trial data point submitted in living of the safety and effectiveness of the vaccine used in a younger paediatric population , which may want a different dose or preparation from that used in an older paediatric population or adult , " Dr. Janet Woodcock , do FDA Commissioner , said in a statementon Oct. 1 about the future advisory committee coming together .
The Oct. 26 group meeting will be livestreamedhere .
Originally issue on Live Science .
